Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $10.45 USD
Change Today -0.27 / -2.52%
Volume 62.8K
CORI On Other Exchanges
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

corium international inc (CORI) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/3/15 - $16.29
52 Week Low
11/17/14 - $4.30
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

corium international inc (CORI) Related Businessweek News

No Related Businessweek News Found

corium international inc (CORI) Details

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; Crest Whitestrips, which are a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company’s products under pipeline comprise AG200-15, a combination hormonal contraceptive patch, which delivers ethinyl estradiol and levonorgestrel hormones has completed a Phase III clinical trial; MicroCor hPTH(1-34), a transdermal system that has completed a Phase I clinical trial for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed a Phase I clinical trial for the treatment of benign prostatic hyperplasia. In addition, it is developing a generic transdermal product for the prevention of nausea and vomiting associated with motion sickness; a generic transdermal product for the treatment of a urologic condition, as well as Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company; Teva Pharmaceuticals USA, Inc.; Par Pharmaceutical, Inc.; Agile Therapeutics, Inc.; and others. The company was incorporated in 1995 and is headquartered in Menlo Park, California.

244 Employees
Last Reported Date: 12/15/14
Founded in 1995

corium international inc (CORI) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $582.3K
Chief Financial Officer
Total Annual Compensation: $467.3K
Chief Technology Officer and Vice President o...
Total Annual Compensation: $392.2K
Compensation as of Fiscal Year 2014.

corium international inc (CORI) Key Developments

Corium International, Inc. Initiates Phase 1 Clinical Trial of Corplex Donepezil Transdermal System for the Treatment of Alzheimer's Disease

Corium International, Inc. announced the commencement of dosing in a Phase 1 clinical trial to evaluate the safety, pharmacokinetics and pharmacodynamics of Corplex Donepezil Transdermal System for the sustained and controlled delivery of a treatment for Alzheimer's disease. The product, which is based on Corium's proprietary transdermal formulation and adhesive technology, is designed to deliver donepezil for up to seven days in a single-patch application. The Phase 1 study is a single-dose, crossover study of 12 subjects in the age group representative of Alzheimer's disease. The primary objective of the study is to assess the pharmacokinetic profile of two Corplex Donepezil formulations over seven days, compared to the Aricept tablet. The secondary objectives are assessment of safety and skin tolerability, and evaluation of pharmacodynamics by measuring changes in concentrations of a well-characterized biomarker. The trial, which is expected to be completed in late 2015, follows extensive preclinical evaluation in predictive human skin and animal models that demonstrated sustained delivery over a seven-day period. Corium is also developing a second Alzheimer's disease product candidate, a transdermal patch delivering memantine, which is expected to enter Phase 1 clinical trials during the fourth calendar quarter of 2015.

Corium International Seeks Acquisition

Corium International, Inc. (NasdaqGM:CORI) has commenced an underwritten public offering of 4 million shares of its common stock. It intends to use the net proceeds for general corporate purposes, acquisitions or investments in businesses, products or technologies that are complementary to its own and capital expenditures.

Corium International Mulls Acquisitions

Corium International, Inc. (NasdaqGM:CORI) is seeking acquisitions. Corium International, Inc. has filed a follow-on equity offering. Corium intends to use the net proceeds from the offering for general corporate purposes, which may include funding research and development, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to its own and capital expenditures.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CORI:US $10.45 USD -0.27

CORI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $142.83 USD -0.12
FUJIFILM Holdings Corp ¥4,986 JPY -5.50
Mylan NV $50.37 USD -1.12
Zogenix Inc $18.41 USD +1.35
Zosano Pharma Corp $8.10 USD +0.05
View Industry Companies

Industry Analysis


Industry Average

Valuation CORI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.4x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CORIUM INTERNATIONAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at